Session: 263. HIV: ART Resistance & Adherence, Saturday, 12:15-1:30 p.m.
Background : This study compared yearly and longer term antiretroviral (ARV) adherence among HIV patients overall and by single-tablet regimens (STRs) vs. multi-tablet regimens (MTRs).
Methods : A retrospective study using Optum Clinformatics US-based claims data was conducted. Patients with an HIV-1 diagnosis during 2011-2017, age ≥ 18 years at index (date of first complete ARV regimen during the study period), and continuous enrollment for ≥ 3 months before index (baseline) and ≥ 12 months after index (observation) were included. MTRs were required to be comprised of 3 or more agents across at least 2 classes. Adherence was measured as the proportion of days covered (PDC) and compared using a Chi-square test. PDC was examined in the 1-year observation period for the overall analysis, and each year following index among patients with at least 4 years of continuous data. A subgroup analysis was conducted among patients with index during 2014-2016 to evaluate modern ARV adherence.
Results : Among the 15,153 included patients, median age was 45 years, the majority were male (88%), and 53% were in the South. At baseline, 58% (n = 8,715) were receiving an STR and 43% (n = 6,438) an MTR. Compared to STR patients, MTR patients had higher prevalence of hyperlipidemia (36% vs. 29%), cardiovascular disease (27% vs. 21%), and hypertension (25% vs. 20%). During year 1, the proportion of patients with PDC ≥ 0.90 was 63% overall (Table 1), and greater for STR than MTR (67% vs. 58%, P < .001). Among patients with at least 4 years of observation, PDC ≥ 0.90 decreased over time (from 67% in year 1 to 53% in year 4). In the subgroup of patients with index during 2014-2016 (Table 2), similar but slightly worse trends were observed, with PDC ≥ 0.90 for 57% of patients overall, and decreasing over time for those patients with at least 3 years of observation (59% in year 1 to 42% in year 3).
Conclusion : Adherence in this population of patients with HIV showed room for improvement in the first year of observation overall and in the modern ARV era, with those receiving STRs having higher adherence as compared to those receiving MTRs. For the patients with 4 years of follow-up, adherence tended to decrease year on year. Maintaining high rates of ARV adherence is a critically important aspect of therapy for patients with HIV.
Julie Priest– Director, ViiV Healthcare, Durham, NC
Rachel Bhak– Associate, Analysis Group, Inc., Boston, MA
Maral DerSarkissian– Manager, Analysis Group, Inc., Los Angeles, CA
Cindy Garris– Director, ViiV Healthcare, Raleigh, NC
Alan Oglesby– Sr. Director, ViiV Healthcare, Research Triangle Park, NC
Colin Kunzweiler– Associate and Epidemiologist, Analysis Group, Boston, MA
Ellie Fuqua– Analyst, Analysis Group, Boston, MA
Suna Park– Analyst, Analysis Group, Boston, MA
Mei Sheng Duh– Managing Principal, Analysis Group, Inc., Analysis Group, Inc., MA